IDEAS home Printed from https://ideas.repec.org/d/ohecouk.html

Publications

by members of

Office of Health Economics

These are publications listed in RePEc written by members of the above institution who are registered with the RePEc Author Service. Thus this compiles the works all those currently affiliated with this institution, not those affilated at the time of publication. List of registered members. Register yourself. Citation analysis. This page is updated in the first days of each month.
| Working papers | Journal articles | Books |

Working papers

2026

  1. Sam Large & Joe Trim & Ella Barker & Louis Zanden & Phill O’Neill & Chris Sampson, 2026, "The impact of inflation on incremental costs in HTA," Contract Research, Office of Health Economics, number 002533, Jun.

2025

  1. Henry Fong & Priscila Radu & Nadine Henderson & Martina Garau & Lotte Steuten, 2025, "A global landscape analysis of access to tumour-agnostic therapies," Contract Research, Office of Health Economics, number 002524, Dec.
  2. Samantha Nier & Claud Theakston & Priscila Radu & David Mott & Nadine Henderson, 2025, "Capturing the lived experiences of informal care in acute leukemia," Grant-Funded Research, Office of Health Economics, number 002525, Nov.
  3. Chris Sampson & Sukanya Subramaniyan & Matthew Napier & Hania El Banhawi & Panos Kefalas & Laura Beswick & Jacqueline Barry & Matthew Durdy & Grace Hampson, 2025, "The value of cell and gene therapies to the UK economy," Contract Research, Office of Health Economics, number 002513, Oct.

2024

  1. Matthew Napier;Chris Sampson;Amanda Cole;Martina Garau, 2024, "A Framework for Value-aligned Pricing of Combination Therapies," Contract Research, Office of Health Economics, number 002490, Jun.

2023

  1. Chris Sampson;Edward Oliver;Priscila Radu;Tanja Podkonjak;Lotte Steuten, 2023, "The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe," Contract Research, Office of Health Economics, number 002468, Jun.

2022

  1. Dimitrios Kourouklis & Mikel Berdud & Mireia Jofre-Bonet & Adrian Towse, 2022, "Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases," Post-Print, HAL, number hal-03710938, Jun, DOI: 10.1080/13504851.2022.2095335.
  2. Adrian Towse & Rachel Silverman Bonnifield, 2022, "An Ambitious USG Advanced Commitment for Subscription-Based Purchasing of Novel Antimicrobials and Its Expected Return on Investment," Policy Papers, Center for Global Development, number 277, Nov.

2021

  1. David Mott;Gayathri Kumar;Chris Sampson;Martina Garau, 2021, "How is Quality of Life Measured for Health Technology Assessments?," Briefing, Office of Health Economics, number 002357, Jul.

2020

  1. Chris Sampson;David Parkin;Nancy Devlin, 2020, "Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation?," Grant-Funded Research, Office of Health Economics, number 002308, Nov.
  2. Adrian Towse, 2020, "How Should the World Pay for a COVID-19 Vaccine?," Monograph, Office of Health Economics, number 002287, Jul.

2019

  1. Mikel Berdud & Kalipso Chalkidou & Emma Dean & Jimena Ferraro & Lou Garrison & Cassandra Nemzoff & Adrian Towse, 2019, "The Future of Global Health Procurement: Issues around Pricing Transparency," Working Papers, Center for Global Development, number 507, Apr.
  2. Amanda Cole;Adrian Towse;Bernarda Zamora, 2019, "Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?," Briefing, Office of Health Economics, number 002165, May.
  3. Amanda Cole;Adrian Towse;Bernarda Zamora, 2019, "Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?," Briefing, Office of Health Economics, number 002176, Jun.
  4. Yaman, F. & Cubi-Molla, P. & Ungureanu, S., 2019, "Which Decision Theory Describes Life Satisfaction Best? Evidence from Annual Panel Data," Working Papers, Department of Economics, City St George's, University of London, number 19/12.
  5. Chris Sampson;Martina Garau, 2019, "How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy," Briefing, Office of Health Economics, number 002146, Mar.

2018

  1. Margherita Neri;Adrian Towse;Martina Garau, 2018, "Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward," Briefing, Office of Health Economics, number 002084, Dec.
  2. Jofre-Bonet, Mireia & Kamara, Joseph, 2018, "Willingness to pay for health insurance in the informal sector of Sierra Leone," LSE Research Online Documents on Economics, London School of Economics and Political Science, LSE Library, number 89836, May.
  3. Paula Lorgelly;Amanda Cole;Phill O’Neill;Chris Sampson, 2018, "Barriers to Uptake of Minimal Access Surgery in the United Kingdom," Contract Research, Office of Health Economics, number 001976, Mar.
  4. Chris Sampson;Phill O’Neill;Paula Lorgelly, 2018, "The Impact of New Medicines in the NHS: 70 Years of Innovation," Contract Research, Office of Health Economics, number 002047, Aug.
  5. Mikel Berdud;Martina Garau;Margherita Neri;Phill O’Neill;Chris Sampson;Adrian Towse, 2018, "R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C," Grant-Funded Research, Office of Health Economics, number 002040, Jul.

2017

  1. Adrian Towse;Jimena Ferraro;Jorge Mestre-Ferrandiz, 2017, "Incentives for New Drugs to Tackle Anti-Microbial Resistance," Briefing, Office of Health Economics, number 001842, May.
  2. Margherita Neri;Adrian Towse, 2017, "Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?," Briefing, Office of Health Economics, number 001922, Oct.

2016

  1. Amanda Cole;Adrian Towse;Michelle Mujoomdar;Arnold Chan;Franz Pichler, 2016, "How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?," Briefing, Office of Health Economics, number 001740, Aug.
  2. Amanda Cole;Grace Hampson;Nancy Devlin;David Grainger;Eui-Kyung Lee;Wija Oortwijn, 2016, "“New Age” Decision Making in HTA: Is It Applicable in Asia?," Briefing, Office of Health Economics, number 001741, Aug.
  3. Joan Costa-i-Font & Mireia Jofre-Bonet, 2016, "Like Mother, Like Father? Gender Assortative Transmission of Child Overweight," CESifo Working Paper Series, CESifo, number 5985.

2015

  1. Amanda Cole, 2015, "Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK," Contract Research, Office of Health Economics, number 001595, Mar.
  2. Joan Costa-i-Font & Mireia Jofre-Bonet & Julian Le Grand, 2015, "Vertical Transmission of Overweight: Evidence from English Adoptees," CESifo Working Paper Series, CESifo, number 5351.
  3. Sarah Karlsberg-Schaffer;Jon Sussex;Yan Feng, 2015, "Incentives to follow Best Practice in Health Care," Briefing, Office of Health Economics, number 001583, Feb.
  4. Jorge Mestre-Ferrandiz;Renato Dellamano;Michele Pistollato;Adrian Towse, 2015, "Multi-indication Pricing: Pros, Cons and Applicability to the UK," Seminar Briefing, Office of Health Economics, number 001653, Oct.

2014

  1. Mikel Berdud & Juan M. Cabasés Hita & Jorge Nieto, 2014, "Motivational Capital and Incentives in Health Care Organizations," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra, Departamento de Economía - Universidad Pública de Navarra, number 1403.
  2. Mikel Berdud & Juan M. Cabasés Hita & Jorge Nieto, 2014, "A Pilot Inquiry on Incentives and Intrinsic Motivation in Health Care: the Motivational Capital Explained by Doctors," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra, Departamento de Economía - Universidad Pública de Navarra, number 1401.
  3. Jofre-Bonet, Mireia & Pesendorfer, Martin, 2014, "Optimal sequential auctions," LSE Research Online Documents on Economics, London School of Economics and Political Science, LSE Library, number 56438, Mar.
  4. Adrian Towse, 2014, "Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?," Occasional Paper, Office of Health Economics, number 001561, Dec.

2013

  1. Cubi-Molla, P. & Jofre-Bonet, M. & Serra-Sastre, V., 2013, "Adaptation to Health States: A Micro-Econometric Approach," Working Papers, Department of Economics, City St George's, University of London, number 13/02.
  2. Cubi-Molla, P. & De Vries, J. & Devlin, N., 2013, "A Study of the Relationship Between Health and Subjective Well-being in Parkinson’s Disease Patients," Working Papers, Department of Economics, City St George's, University of London, number 13/12.
  3. Karl Claxton & Steve Martin & Marta Soares & Nigel Rice & Eldon Spackman & Sebastian Hinde & Nancy Devlin & Peter C Smith & Mark Sculpher, 2013, "Methods for the estimation of the NICE cost effectiveness threshold," Working Papers, Centre for Health Economics, University of York, number 081cherp, Jan.
  4. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O’Neill & David Parkin, 2013, "The influence of cost-effectiveness and other factors on NICE decisions," Working Papers, Centre for Health Economics, University of York, number 093cherp, Nov.
  5. Joan Costa-i-Font & Mireia Jofre-Bonet, 2013, "In brief...Eating disorders: the impact of self-image and peer pressure," CentrePiece - The magazine for economic performance, Centre for Economic Performance, LSE, number 406, Dec.
  6. Adrian Towse;Paul Barnsley;Sarah Karlsberg-Schaffer;Jon Sussex, 2013, "Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold," Occasional Paper, Office of Health Economics, number 000106, Dec.
  7. Sampson, Christopher & James, Marilyn & Huband, Nick & Geelan, Steve & McMurran, Mary, 2013, "Cost implications of treatment non-completion in a forensic personality disorder service," MPRA Paper, University Library of Munich, Germany, number 48757, Jul.
  8. Hernández-Alava, Mónica & Sampson, Christopher & Wailoo, Allan, 2013, "Happy and healthy: a joint model of health and life satisfaction," MPRA Paper, University Library of Munich, Germany, number 49766, Sep.
  9. Sampson, Christopher & James, Marilyn & Whynes, David, 2013, "The relationship between individual risk and cost-effectiveness in screening interventions," MPRA Paper, University Library of Munich, Germany, number 51799, Nov.

2012

  1. Mikel Berdud & Juan M. Cabasés & Jorge Nieto, 2012, "Incentives Beyond the Money: Identity and Motivational Capital in Public Organizations," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra, Departamento de Economía - Universidad Pública de Navarra, number 1214.
  2. Mikel Berdud & Juan M. Cabasés Hita, 2012, "Incentives Beyond the Money and Motivational Capital in Health Care Organizations," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra, Departamento de Economía - Universidad Pública de Navarra, number 1201.
  3. Nils Gutacker & Chris Bojke & Silvio Daidone & Nancy Devlin & Andrew Street, 2012, "Analysing Hospital Variation in Health Outcome at the Level of EQ-5D Dimensions," Working Papers, Centre for Health Economics, University of York, number 074cherp, Jan.
  4. Versteegh, MM & Attema, AE & Oppe, M & Devlin, NJ & Stolk, EA, 2012, "Time to tweak the TTO. But how?," MPRA Paper, University Library of Munich, Germany, number 37989, Mar.
  5. Patricia M. Danzon & Adrian K. Towse & Jorge Mestre-Ferrandiz, 2012, "Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context," NBER Working Papers, National Bureau of Economic Research, Inc, number 18593, Dec.
  6. Lou Garrison;Ruth Puig-Peiro;Adrian Towse, 2012, "The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?," Occasional Paper, Office of Health Economics, number 000167, Feb.

2011

  1. Cubí-Mollá Patricia & Herrero Carmen, 2011, "Quality of Life Lost Due to Non-Fatal Road Crashes," Working Papers, Fundacion BBVA / BBVA Foundation, number 2011104, Jan.
  2. Nils Gutacker & Chris Bojke & Silvio Daidone & Nancy Devlin & David Parkin & Andrew Street, 2011, "Truly inefficient or providing better quality of care? Analysing the relationship between riskadjusted hospital costs and patients’ health outcomes," Working Papers, Centre for Health Economics, University of York, number 068cherp, Oct.
  3. Patricia Danzon;Martina Garau;Adrian Towse, 2011, "Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?," Occasional Paper, Office of Health Economics, number 000191, Feb.
  4. Joan Costa Font & Mireia Jofre-Bonet, 2011, "Anorexia, Body Image and Peer Effects: Evidence from a Sample of European Women," CEP Discussion Papers, Centre for Economic Performance, LSE, number dp1098, Nov.
  5. Joan Costa-i-Font & Mireia Jofre-Bonet & Steven T. Yen, 2011, "Not All Incentives Wash Out the Warm Glow: The Case of Blood Donation Revisited," CESifo Working Paper Series, CESifo, number 3527.
  6. Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2011, "Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement," NBER Working Papers, National Bureau of Economic Research, Inc, number 17174, Jun.

2010

  1. Patricia Cubí Mollá, 2010, "Scaling methods for categorical self-assessed health measures," Working Papers. Serie AD, Instituto Valenciano de Investigaciones Económicas, S.A. (Ivie), number 2010-01, Jan.
  2. Priya Sharma;Adrian Towse, 2010, "New Drugs to Tackle Antimicrobial Resistance: EU Policy Options," Occasional Paper, Office of Health Economics, number 000216, Oct.

2009

  1. Jorge Mestre-Ferrandiz;Martina Garau, 2009, "Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries," Briefing, Office of Health Economics, number 000227, Nov.
  2. Costa-Font, Joan & Jofre-Bonet, Mireia, 2009, "Body image, peer effects and food disorders: evidence from a sample of European women," LSE Research Online Documents on Economics, London School of Economics and Political Science, LSE Library, number 27751, Nov.
  3. Devlin, N. & Parkin, D. & Browne, J., 2009, "Using the EQ-5D as a performance measurement tool in the NHS," Working Papers, Department of Economics, City St George's, University of London, number 09/03.

2008

  1. Joan Costa i Font & Mireia Jofre-Bonet, 2008, "Body image and food disorders: Evidence from a sample of European women," Working Papers, FEDEA, number 2008-30, Sep.
  2. Albert Banal-Estañol & Mireia Jofre-Bonet & Cornelia Meissner, 2008, "Theimpact of industry collaboration on research: Evidence from engineering academics in the UK," Economics Working Papers, Department of Economics and Business, Universitat Pompeu Fabra, number 1190, Sep, revised Aug 2010.
  3. Parkin, D. & Rice, N. & Devlin, N., 2008, "Statistical analysis of EQ-5D profiles: does the use of value sets bias inference?," Working Papers, Department of Economics, City St George's, University of London, number 08/10.
  4. Deven Chauhan;Jorge Mestre-Ferrandiz;Adrian Towse, 2008, "The Market for Biosimilars: Evolution and Policy Options," Briefing, Office of Health Economics, number 000238, Nov.

2007

  1. Martina Garau, 2007, "Estimating Pharmaceutical Companies' Value to the Nation: Case Study of the British Pharma Group," Briefing, Office of Health Economics, number 000245, Feb.

2006

  1. Conradie, Beatrice & Cookson, Graham & Thirtle, Colin G., 2006, "Efficiency and Pooling in Western Cape Wine Grape Production," 2006 Annual Meeting, August 12-18, 2006, Queensland, Australia, International Association of Agricultural Economists, number 25522, DOI: 10.22004/ag.econ.25522.
  2. Dimakou, S. & Parkin, D. & Devlin, N. & Appleby, J., 2006, "The impact of government targets on waiting times for elective surgery: new insights from time-to-event analysis," Working Papers, Department of Economics, City St George's, University of London, number 06/05.
  3. Martin Buxton;Adrian Towse, 2006, "Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds," Briefing, Office of Health Economics, number 000267, Oct.

2005

  1. Sadique, Z. & Edmunds, W. J. & Devlin, N. & Parkin, D., 2005, "Understanding individuals’ decisions about vaccination: a comparison between Expected Utility and Regret Theory models," Working Papers, Department of Economics, City St George's, University of London, number 05/03.

2004

  1. Susan H. Busch & Mireia Jofre-Bonet & Tracy A. Falba & Jody L. Sindelar, 2004, "Tobacco Spending and its Crowd-Out of Other Goods," NBER Working Papers, National Bureau of Economic Research, Inc, number 10974, Dec.
  2. Parkin, D. & Devlin, N., 2004, "Is there a case for using Visual Analogue Scale valuations in Cost-Utility Analysis?," Working Papers, Department of Economics, City St George's, University of London, number 04/03.

2003

  1. Paul Fenn;Alastair Gray;Neil Rickman;Rodrigo Salinas;Adrian Towse, 2003, "Reducing Harm to Patients in the National Health Service. Will the Government’s Compensation Proposals Help?," Briefing, Office of Health Economics, number 000484, Dec.

2002

  1. Mireia Jofre-Bonet & Jody L. Sindelar, 2002, "Drug Treatment as a Crime Fighting Tool," NBER Working Papers, National Bureau of Economic Research, Inc, number 9038, Jul.
  2. Tsuchiya, A & Brazier, J & McColl, E & Parkin, D, 2002, "Deriving preference-based single indices from non-preference based condition-specific instruments: converting AQLQ into EQ5D indices," MPRA Paper, University Library of Munich, Germany, number 29740, May.

2001

  1. Mireia Jofre-Bonet & Martin Pesendorfer, 2001, "Estimation of a Dynamic Auction Game," NBER Working Papers, National Bureau of Economic Research, Inc, number 8626, Dec.

2000

  1. Nancy Devlin & Paul Hansen, 2000, "Allocating Vote: Health — ‘Needs Assessment’ and an Economics-Based Approach," Treasury Working Paper Series, New Zealand Treasury, number 00/04.
  2. N J Devlin & P Hansen & P Kind & A H Williams, 2000, "The health state preferences and logistical inconsistencies of New Zealanders: a tale of two tariffs," Working Papers, Centre for Health Economics, University of York, number 180chedp, Jul.
  3. Kobelt, Gisela & Lindgren, Peter & Parkin, David & Francis, David A. & Johnson, Michael & Bates, David & Jönsson, Bengt, 2000, "Costs and Quality of Life in Multiple Sclerosis. A Cross-Sectional Observational Study in the UK," SSE/EFI Working Paper Series in Economics and Finance, Stockholm School of Economics, number 398, Oct.

1998

  1. Michael F. Drummond;Adrian Towse, 1998, "From Efficacy to Cost-Effectiveness," Briefing, Office of Health Economics, number 000438, May.

1997

  1. Martin Cave;Adrian Towse, 1997, "Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry," Briefing, Office of Health Economics, number 000427, Oct.

Journal articles

2026

  1. David Parkin, 2026, "Health State Values Should Not Be Used as Minimal Important Differences," Medical Decision Making, , volume 46, issue 2, pages 119-121, February, DOI: 10.1177/0272989X251388647.
  2. David Parkin & Andrew Briggs & Giselle Abangma & Andrew Lloyd & Nancy Devlin, 2026, "Uncertainty around Health State Values Used in Cost-Effectiveness Analysis: How It Arises and How to Deal with It," Medical Decision Making, , volume 46, issue 2, pages 130-143, February, DOI: 10.1177/0272989X251380556.

2025

  1. Adrian Towse & Andrew Briggs & Lotte Steuten, 2025, "Pricing combination products: not how but who?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 26, issue 4, pages 537-540, June, DOI: 10.1007/s10198-025-01773-8.
  2. Neil Hawkins & Adrian Towse & Amanda Adler, 2025, "Missing Pieces of the Puzzle to Address Market Failures for Antibiotics: Delinked Payment Systems and Insurance Value," PharmacoEconomics - Open, Springer, volume 9, issue 5, pages 707-712, September, DOI: 10.1007/s41669-025-00591-1.

2024

  1. Margherita Neri & Patricia Cubi-Molla & Graham Cookson, 2024, "A Multi-dimensional Framework of Valued Output for Primary Care in England," Applied Health Economics and Health Policy, Springer, volume 22, issue 5, pages 609-617, September, DOI: 10.1007/s40258-024-00895-z.
  2. Chris Sampson & David Parkin & Nancy Devlin, 2024, "Is anchoring at ‘dead’ a theoretical requirement for health state valuation?," Health Economics, John Wiley & Sons, Ltd., volume 33, issue 9, pages 1929-1935, September, DOI: 10.1002/hec.4863.
  3. Yan Feng & Søren Rud Kristensen & Paula Lorgelly & Rachel Meacock & Alberto Núñez-Elvira & Marina Rodés-Sánchez & Luigi Siciliani & Matt Sutton, 2024, "Pay-for-Performance incentives for specialised services in England: a mixed methods evaluation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 25, issue 5, pages 857-876, July, DOI: 10.1007/s10198-023-01630-6.
  4. Sampson, Chris & Cookson, Graham, 2024, "Marginal cost per QALY estimates: What are they good for?," Health Policy, Elsevier, volume 142, issue C, DOI: 10.1016/j.healthpol.2024.105036.

2023

  1. Brassel, Simon & Al Taie, Amer & Steuten, Lotte, 2023, "Value assessment of antimicrobials using the STEDI framework – How steady is the outcome?," Health Policy, Elsevier, volume 136, issue C, DOI: 10.1016/j.healthpol.2023.104892.
  2. Amira El-Shal & Patricia Cubi-Molla & Mireia Jofre-Bonet, 2023, "Discontinuation of performance-based financing in primary health care: impact on family planning and maternal and child health," International Journal of Health Economics and Management, Springer, volume 23, issue 1, pages 109-132, March, DOI: 10.1007/s10754-022-09333-w.
  3. Fırat Yaman & Patricia Cubí-Mollá & Sergiu Ungureanu, 2023, "Which Decision Theory Describes Life Satisfaction Best? Evidence from Annual Panel Data," Journal of Happiness Studies, Springer, volume 24, issue 3, pages 893-916, March, DOI: 10.1007/s10902-023-00627-5.
  4. Chris Skedgel & Patricia Cubi-Molla & David Mott & Sofia Gameiro & Jacky Boivin & Hareth Al-Janabi & John Brazier & Marie Markert & Fredrik L. Andersson & Mireia Jofre-Bonet, 2023, "Unmet Parenthood Goals, Health-Related Quality of Life and Apparent Irrationality: Understanding the Value of Treatments for Infertility," PharmacoEconomics - Open, Springer, volume 7, issue 3, pages 337-344, May, DOI: 10.1007/s41669-023-00402-5.
  5. Dimitrios Kourouklis & Mikel Berdud & Mireia Jofre-Bonet & Adrian Towse, 2023, "Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases," Applied Economics Letters, Taylor & Francis Journals, volume 30, issue 16, pages 2195-2199, September, DOI: 10.1080/13504851.2022.2095335.

2022

  1. Denis Horgan & Bettina Borisch & Ivana Cattaneo & Mark Caulfield & Arturo Chiti & Christine Chomienne & Amanda Cole & Karen Facey & Allan Hackshaw & Minna Hendolin & Nadia Georges & Dipak Kalra & Biru, 2022, "Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare," IJERPH, MDPI, volume 19, issue 3, pages 1-18, February.
  2. Margherita Neri & Patricia Cubi-Molla & Graham Cookson, 2022, "Approaches to Measure Efficiency in Primary Care: A Systematic Literature Review," Applied Health Economics and Health Policy, Springer, volume 20, issue 1, pages 19-33, January, DOI: 10.1007/s40258-021-00669-x.
  3. Chris Sampson & Bernarda Zamora & Sam Watson & John Cairns & Kalipso Chalkidou & Patricia Cubi-Molla & Nancy Devlin & Borja García-Lorenzo & Dyfrig A. Hughes & Ashley A. Leech & Adrian Towse, 2022, "Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy," Applied Health Economics and Health Policy, Springer, volume 20, issue 5, pages 651-667, September, DOI: 10.1007/s40258-022-00730-3.
  4. Cate Bailey & Kim Dalziel & Paula Cronin & Nancy Devlin & Rosalie Viney, 2022, "How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents," PharmacoEconomics, Springer, volume 40, issue 2, pages 157-182, February, DOI: 10.1007/s40273-021-01107-5.
  5. Joseph Kwon & Louise Freijser & Elisabeth Huynh & Martin Howell & Gang Chen & Kamran Khan & Shahd Daher & Nia Roberts & Conrad Harrison & Sarah Smith & Nancy Devlin & Kirsten Howard & Emily Lancsar & , 2022, "Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures," PharmacoEconomics, Springer, volume 40, issue 4, pages 379-431, April, DOI: 10.1007/s40273-021-01128-0.
  6. Cate Bailey & Martin Howell & Rakhee Raghunandan & Amber Salisbury & Gang Chen & Joanna Coast & Jonathan C. Craig & Nancy J. Devlin & Elisabeth Huynh & Emily Lancsar & Brendan J. Mulhern & Richard Nor, 2022, "Preference Elicitation Techniques Used in Valuing Children’s Health-Related Quality-of-Life: A Systematic Review," PharmacoEconomics, Springer, volume 40, issue 7, pages 663-698, July, DOI: 10.1007/s40273-022-01149-3.
  7. Tianxin Pan & Brendan Mulhern & Rosalie Viney & Richard Norman & Janel Hanmer & Nancy Devlin, 2022, "A Comparison of PROPr and EQ-5D-5L Value Sets," PharmacoEconomics, Springer, volume 40, issue 3, pages 297-307, March, DOI: 10.1007/s40273-021-01109-3.
  8. Chris Sampson, 2022, "NICE and the EQ-5D-5L: Ten Years Trouble," PharmacoEconomics - Open, Springer, volume 6, issue 1, pages 5-8, January, DOI: 10.1007/s41669-021-00315-1.

2021

  1. El-Shal, Amira & Cubi-Molla, Patricia & Jofre-Bonet, Mireia, 2021, "Are user fees in health care always evil? Evidence from family planning, maternal, and child health services," Economic Analysis and Policy, Elsevier, volume 72, issue C, pages 506-529, DOI: 10.1016/j.eap.2021.08.009.
  2. Patricia Cubi-Molla & Martin Buxton & Nancy Devlin, 2021, "Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?," Applied Health Economics and Health Policy, Springer, volume 19, issue 5, pages 635-644, September, DOI: 10.1007/s40258-021-00648-2.
  3. Amira El-Shal & Patricia Cubi-Molla & Mireia Jofre-Bonet, 2021, "Accreditation as a quality-improving policy tool: family planning, maternal health, and child health in Egypt," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 22, issue 1, pages 115-139, February, DOI: 10.1007/s10198-020-01240-6.
  4. Andrew J. Palmer & Julie A. Campbell & Barbara de Graaff & Nancy Devlin & Hasnat Ahmad & Philip M Clarke & Mingsheng Chen & Lei Si, 2021, "Population norms for quality adjusted life years for the United States of America, China, the United Kingdom and Australia," Health Economics, John Wiley & Sons, Ltd., volume 30, issue 8, pages 1950-1977, August, DOI: 10.1002/hec.4281.
  5. David J. Mott & Koonal K. Shah & Juan Manuel Ramos-Goñi & Nancy J. Devlin & Oliver Rivero-Arias, 2021, "Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?," Medical Decision Making, , volume 41, issue 5, pages 584-596, July, DOI: 10.1177/0272989X21999607.
  6. Tessa Peasgood & Clara Mukuria & Jill Carlton & Janice Connell & Nancy Devlin & Karen Jones & Rosemary Lovett & Bhash Naidoo & Stacey Rand & Juan Carlos Rejon-Parrilla & Donna Rowen & Aki Tsuchiya & J, 2021, "What is the best approach to adopt for identifying the domains for a new measure of health, social care and carer-related quality of life to measure quality-adjusted life years? Application to the development of the EQ-HWB?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 22, issue 7, pages 1067-1081, September, DOI: 10.1007/s10198-021-01306-z.
  7. Cristina Gutierrez-Delgado & Rosa-María Galindo-Suárez & Cesar Cruz-Santiago & Koonal Shah & Manny Papadimitropoulos & Yan Feng & Bernarda Zamora & Nancy Devlin, 2021, "EQ-5D-5L Health-State Values for the Mexican Population," Applied Health Economics and Health Policy, Springer, volume 19, issue 6, pages 905-914, November, DOI: 10.1007/s40258-021-00658-0.
  8. Richard De Abreu Lourenço & Nancy Devlin & Kirsten Howard & Jason J. Ong & Julie Ratcliffe & Jo Watson & Esther Willing & Elisabeth Huynh, 2021, "Giving a Voice to Marginalised Groups for Health Care Decision Making," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, volume 14, issue 1, pages 5-10, January, DOI: 10.1007/s40271-020-00456-1.
  9. Chris Sampson & Isobel Firth & Adrian Towse, 2021, "Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al," Medical Decision Making, , volume 41, issue 3, pages 255-257, April, DOI: 10.1177/0272989X20987211.
  10. Kyann Zhang & Gayathri Kumar & Chris Skedgel, 2021, "Towards a New Understanding of Unmet Medical Need," Applied Health Economics and Health Policy, Springer, volume 19, issue 6, pages 785-788, November, DOI: 10.1007/s40258-021-00655-3.

2020

  1. Paula Lorgelly & Jack Pollard & Patricia Cubi-Molla & Amanda Cole & Duncan Sim & Jon Sussex, 2020, "Outcome-Based Payment Schemes: What Outcomes Do Patients with Cancer Value?," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, volume 13, issue 5, pages 599-610, October, DOI: 10.1007/s40271-020-00430-x.
  2. Sullivan, Trudy & Hansen, Paul & Ombler, Franz & Derrett, Sarah & Devlin, Nancy, 2020, "A new tool for creating personal and social EQ-5D-5L value sets, including valuing ‘dead’," Social Science & Medicine, Elsevier, volume 246, issue C, DOI: 10.1016/j.socscimed.2019.112707.
  3. Donna Rowen & Oliver Rivero-Arias & Nancy Devlin & Julie Ratcliffe, 2020, "Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?," PharmacoEconomics, Springer, volume 38, issue 4, pages 325-340, April, DOI: 10.1007/s40273-019-00873-7.
  4. Juan M. Ramos-Goñi & Mark Oppe & Elly Stolk & Koonal Shah & Simone Kreimeier & Oliver Rivero-Arias & Nancy Devlin, 2020, "International Valuation Protocol for the EQ-5D-Y-3L," PharmacoEconomics, Springer, volume 38, issue 7, pages 653-663, July, DOI: 10.1007/s40273-020-00909-3.
  5. Zhang, Angela & Prang, Khic-Houy & Devlin, Nancy & Scott, Anthony & Kelaher, Margaret, 2020, "The impact of price transparency on consumers and providers: A scoping review," Health Policy, Elsevier, volume 124, issue 8, pages 819-825, DOI: 10.1016/j.healthpol.2020.06.001.
  6. Koonal K. Shah & Juan Manuel Ramos-Goñi & Simone Kreimeier & Nancy J. Devlin, 2020, "An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 21, issue 7, pages 1091-1103, September, DOI: 10.1007/s10198-020-01205-9.
  7. Hobbins, Anna P. & Barry, Luke & Kelleher, Dan & Shah, Koonal & Devlin, Nancy & Ramos Goni, Juan Manuel & O’Neill, Ciaran, 2020, "Do people with private health insurance attach a higher value to health than those without insurance? Results from an EQ-5D-5 L valuation study in Ireland," Health Policy, Elsevier, volume 124, issue 6, pages 639-646, DOI: 10.1016/j.healthpol.2020.03.005.
  8. David J. Mott & Grace Hampson & Martin J. Llewelyn & Jorge Mestre-Ferrandiz & Michael M. Hopkins, 2020, "A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance," Applied Health Economics and Health Policy, Springer, volume 18, issue 1, pages 69-79, February, DOI: 10.1007/s40258-019-00516-0.
  9. David J. Mott & Grace Hampson & Martin J. Llewelyn & Jorge Mestre-Ferrandiz & Michael M. Hopkins, 2020, "Authors’ Reply to Hays: “A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance”," Applied Health Economics and Health Policy, Springer, volume 18, issue 3, pages 459-460, June, DOI: 10.1007/s40258-020-00573-w.
  10. Nils Gutacker & Thomas Patton & Koonal Shah & David Parkin, 2020, "Using EQ-5D Data to Measure Hospital Performance: Are General Population Values Distorting Patients’ Choices?," Medical Decision Making, , volume 40, issue 4, pages 511-521, May, DOI: 10.1177/0272989X20927705.

2019

  1. Nancy J. Devlin & Koonal K. Shah & Brendan J. Mulhern & Krystallia Pantiri & Ben van Hout, 2019, "A new method for valuing health: directly eliciting personal utility functions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 20, issue 2, pages 257-270, March, DOI: 10.1007/s10198-018-0993-z.
  2. Fan Yang & Nancy Devlin & Nan Luo, 2019, "Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 20, issue 1, pages 99-105, February, DOI: 10.1007/s10198-018-0987-x.
  3. Nancy J. Devlin, 2019, "All Male Panels and Other Diversity Considerations for ISPOR," PharmacoEconomics - Open, Springer, volume 3, issue 3, pages 423-426, September, DOI: 10.1007/s41669-019-0169-5.
  4. Bengt Jönsson & Grace Hampson & Jonathan Michaels & Adrian Towse & J.-Matthias Graf Schulenburg & Olivier Wong, 2019, "Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 20, issue 3, pages 427-438, April, DOI: 10.1007/s10198-018-1007-x.
  5. Pickles, Kristen & Lancsar, Emily & Seymour, Janelle & Parkin, David & Donaldson, Cam & Carter, Stacy M., 2019, "Accounts from developers of generic health state utility instruments explain why they produce different QALYs: A qualitative study," Social Science & Medicine, Elsevier, volume 240, issue C, DOI: 10.1016/j.socscimed.2019.112560.
  6. Christopher James Sampson & Renée Arnold & Stirling Bryan & Philip Clarke & Sean Ekins & Anthony Hatswell & Neil Hawkins & Sue Langham & Deborah Marshall & Mohsen Sadatsafavi & Will Sullivan & Edward , 2019, "Transparency in Decision Modelling: What, Why, Who and How?," PharmacoEconomics, Springer, volume 37, issue 11, pages 1355-1369, November, DOI: 10.1007/s40273-019-00819-z.
  7. Michael Drummond & Adrian Towse, 2019, "Is rate of return pricing a useful approach when value-based pricing is not appropriate?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 20, issue 7, pages 945-948, September, DOI: 10.1007/s10198-019-01032-7.

2018

  1. Amanda Cole & Koonal Shah & Brendan Mulhern & Yan Feng & Nancy Devlin, 2018, "Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 19, issue 4, pages 595-605, May, DOI: 10.1007/s10198-017-0905-7.
  2. Graham Cookson & Ioannis Laliotis, 2018, "Promoting normal birth and reducing caesarean section rates: An evaluation of the Rapid Improvement Programme," Health Economics, John Wiley & Sons, Ltd., volume 27, issue 4, pages 675-689, April, DOI: 10.1002/hec.3624.
  3. Patricia Cubi-Molla & Koonal Shah & Kristina Burström, 2018, "Experience-Based Values: A Framework for Classifying Different Types of Experience in Health Valuation Research," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, volume 11, issue 3, pages 253-270, June, DOI: 10.1007/s40271-017-0292-2.
  4. Yan Feng & Nancy J. Devlin & Koonal K. Shah & Brendan Mulhern & Ben van Hout, 2018, "New methods for modelling EQ‐5D‐5L value sets: An application to English data," Health Economics, John Wiley & Sons, Ltd., volume 27, issue 1, pages 23-38, January, DOI: 10.1002/hec.3560.
  5. Nancy J. Devlin & Koonal K. Shah & Yan Feng & Brendan Mulhern & Ben van Hout, 2018, "Valuing health‐related quality of life: An EQ‐5D‐5L value set for England," Health Economics, John Wiley & Sons, Ltd., volume 27, issue 1, pages 7-22, January, DOI: 10.1002/hec.3564.
  6. Nancy Devlin & John Brazier & A. Simon Pickard & Elly Stolk, 2018, "3L, 5L, What the L? A NICE Conundrum," PharmacoEconomics, Springer, volume 36, issue 6, pages 637-640, June, DOI: 10.1007/s40273-018-0622-9.
  7. Anna Hobbins & Luke Barry & Dan Kelleher & Koonal Shah & Nancy Devlin & Juan Manuel Ramos Goni & Ciaran O’Neill, 2018, "Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L," PharmacoEconomics, Springer, volume 36, issue 11, pages 1345-1353, November, DOI: 10.1007/s40273-018-0690-x.
  8. Martina Garau & Grace Hampson & Nancy Devlin & Nicola Amedeo Mazzanti & Antonio Profico, 2018, "Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)," PharmacoEconomics - Open, Springer, volume 2, issue 2, pages 153-163, June, DOI: 10.1007/s41669-017-0048-x.
  9. Brendan Mulhern & Yan Feng & Koonal Shah & Mathieu F. Janssen & Michael Herdman & Ben Hout & Nancy Devlin, 2018, "Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets," PharmacoEconomics, Springer, volume 36, issue 6, pages 727-727, June, DOI: 10.1007/s40273-018-0648-z.
  10. Camilleri, Carl & Jofre-Bonet, Mireia & Serra-Sastre, Victoria, 2018, "The suitability of a DRG casemix system in the Maltese hospital setting," Health Policy, Elsevier, volume 122, issue 11, pages 1183-1189, DOI: 10.1016/j.healthpol.2018.08.002.
  11. Jofre-Bonet, Mireia & Serra-Sastre, Victoria & Vandoros, Sotiris, 2018, "The impact of the Great Recession on health-related risk factors, behaviour and outcomes in England," Social Science & Medicine, Elsevier, volume 197, issue C, pages 213-225, DOI: 10.1016/j.socscimed.2017.12.010.
  12. Gerard Harty & James Jarrett & Mireia Jofre-Bonet, 2018, "Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work," Applied Health Economics and Health Policy, Springer, volume 16, issue 4, pages 515-525, August, DOI: 10.1007/s40258-018-0395-5.

2017

  1. Emma Cowles & Grace Marsden & Amanda Cole & Nancy Devlin, 2017, "A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?," Applied Health Economics and Health Policy, Springer, volume 15, issue 4, pages 469-477, August, DOI: 10.1007/s40258-017-0309-y.
  2. Graham Cookson & Simon Jones & Ioannis Laliotis, 2017, "Cancelled Procedures in the English NHS: Evidence from the 2010 Tariff Reform," Health Economics, John Wiley & Sons, Ltd., volume 26, issue 12, pages 126-139, December, DOI: 10.1002/hec.3486.
  3. Patricia Cubí‐Mollá & Mireia Jofre‐Bonet & Victoria Serra‐Sastre, 2017, "Adaptation to health states: Sick yet better off?," Health Economics, John Wiley & Sons, Ltd., volume 26, issue 12, pages 1826-1843, December, DOI: 10.1002/hec.3509.
  4. Paul F. M. Krabbe & Elly A. Stolk & Nancy J. Devlin & Feng Xie & Elise H. Quik & A. Simon Pickard, 2017, "Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 18, issue 8, pages 967-977, November, DOI: 10.1007/s10198-016-0841-y.
  5. Mike Herdman & Jameel Nazir & Zalmai Hakimi & Emad Siddiqui & Moses Huang & Marco Pavesi & Scott MacDiarmid & Marcus J. Drake & Nancy Devlin, 2017, "Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, volume 10, issue 6, pages 677-686, December, DOI: 10.1007/s40271-017-0262-8.
  6. Nancy J. Devlin & Richard Brooks, 2017, "EQ-5D and the EuroQol Group: Past, Present and Future," Applied Health Economics and Health Policy, Springer, volume 15, issue 2, pages 127-137, April, DOI: 10.1007/s40258-017-0310-5.
  7. Yan Feng & Toby Watt & Anita Charlesworth & Grace Marsden & Adam Roberts & Jon Sussex, 2017, "What Determines the Health Care Expenditure of High Income Countries? A Dynamic Estimation," Applied Economics and Finance, Redfame publishing, volume 4, issue 6, pages 1-16, November.
  8. Christopher James Sampson & Tim Wrightson, 2017, "Model Registration: A Call to Action," PharmacoEconomics - Open, Springer, volume 1, issue 2, pages 73-77, June, DOI: 10.1007/s41669-017-0019-2.
  9. Towse, Adrian & Hoyle, Christopher K. & Goodall, Jonathan & Hirsch, Mark & Mestre-Ferrandiz, Jorge & Rex, John H., 2017, "Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation," Health Policy, Elsevier, volume 121, issue 10, pages 1025-1030, DOI: 10.1016/j.healthpol.2017.07.011.

2016

  1. Mikel Berdud & Adrian Towse & Hannah Kettler, 2016, "Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria," Oxford Review of Economic Policy, Oxford University Press and Oxford Review of Economic Policy Limited, volume 32, issue 1, pages 64-87.
  2. Jorge Mestre-Ferrandiz & Adrian Towse & Mikel Berdud, 2016, "Biosimilars: How Can Payers Get Long-Term Savings?," PharmacoEconomics, Springer, volume 34, issue 6, pages 609-616, June, DOI: 10.1007/s40273-015-0380-x.
  3. David Parkin & Nancy Devlin & Yan Feng, 2016, "What Determines the Shape of an EQ-5D Index Distribution?," Medical Decision Making, , volume 36, issue 8, pages 941-951, November, DOI: 10.1177/0272989X16645581.

2015

  1. Karlsberg Schaffer, Sarah & Sussex, Jon & Devlin, Nancy & Walker, Andrew, 2015, "Local health care expenditure plans and their opportunity costs," Health Policy, Elsevier, volume 119, issue 9, pages 1237-1244, DOI: 10.1016/j.healthpol.2015.07.007.
  2. David Nuttall & David Parkin & Nancy Devlin, 2015, "Inter‐Provider Comparison Of Patient‐Reported Outcomes: Developing An Adjustment To Account For Differences In Patient Case Mix," Health Economics, John Wiley & Sons, Ltd., volume 24, issue 1, pages 41-54, January, DOI: 10.1002/hec.2999.
  3. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O'Neill & David Parkin, 2015, "The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions," Health Economics, John Wiley & Sons, Ltd., volume 24, issue 10, pages 1256-1271, October, DOI: 10.1002/hec.3086.
  4. Feng Xie & A. Pickard & Paul Krabbe & Dennis Revicki & Rosalie Viney & Nancy Devlin & David Feeny, 2015, "A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)," PharmacoEconomics, Springer, volume 33, issue 8, pages 867-877, August, DOI: 10.1007/s40273-015-0292-9.
  5. Banal-Estañol, Albert & Jofre-Bonet, Mireia & Lawson, Cornelia, 2015, "The double-edged sword of industry collaboration: Evidence from engineering academics in the UK," Research Policy, Elsevier, volume 44, issue 6, pages 1160-1175, DOI: 10.1016/j.respol.2015.02.006.
  6. Sarah Karlsberg Schaffer, 2015, "The Effect of Free Personal Care for the Elderly on Informal Caregiving," Health Economics, John Wiley & Sons, Ltd., volume 24, issue S1, pages 104-117, March, DOI: 10.1002/hec.3146.
  7. Adrian Towse & Michele Pistollato & Jorge Mestre-Ferrandiz & Zeba Khan & Satyin Kaura & Louis Garrison, 2015, "European Union Pharmaceutical Markets: A Case for Differential Pricing?," International Journal of the Economics of Business, Taylor & Francis Journals, volume 22, issue 2, pages 263-275, July, DOI: 10.1080/13571516.2015.1045747.
  8. Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2015, "Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement," Health Economics, John Wiley & Sons, Ltd., volume 24, issue 2, pages 238-252, February, DOI: 10.1002/hec.3013.
  9. Patricia Danzon & Adrian Towse & Jorge Mestre‐Ferrandiz, 2015, "Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context," Health Economics, John Wiley & Sons, Ltd., volume 24, issue 3, pages 294-301, March, DOI: 10.1002/hec.3021.

2014

  1. A. Chapman & C. Taylor & A. Girling, 2014, "Are the UK Systems of Innovation and Evaluation of Medical Devices Compatible? The Role of NICE’s Medical Technologies Evaluation Programme (MTEP)," Applied Health Economics and Health Policy, Springer, volume 12, issue 4, pages 347-357, August, DOI: 10.1007/s40258-014-0104-y.
  2. Blanc-Brude, Frédéric & Cookson, Graham & Piesse, Jenifer & Strange, Roger, 2014, "The FDI location decision: Distance and the effects of spatial dependence," International Business Review, Elsevier, volume 23, issue 4, pages 797-810, DOI: 10.1016/j.ibusrev.2013.12.002.
  3. Jofre-Bonet, Mireia & Pesendorfer, Martin, 2014, "Optimal sequential auctions," International Journal of Industrial Organization, Elsevier, volume 33, issue C, pages 61-71, DOI: 10.1016/j.ijindorg.2014.02.002.
  4. Michael Drummond & Adrian Towse, 2014, "Orphan drugs policies: a suitable case for treatment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 15, issue 4, pages 335-340, May, DOI: 10.1007/s10198-014-0560-1.

2013

  1. Graham Cookson & Simon Jones & Bryan McIntosh, 2013, "Cancelled Procedures: Inequality, Inequity And The National Health Service Reforms," Health Economics, John Wiley & Sons, Ltd., volume 22, issue 7, pages 870-876, July, DOI: 10.1002/hec.2860.
  2. Jon Sussex & Adrian Towse & Nancy Devlin, 2013, "Operationalizing Value-Based Pricing of Medicines," PharmacoEconomics, Springer, volume 31, issue 1, pages 1-10, January, DOI: 10.1007/s40273-012-0001-x.
  3. Matthijs Versteegh & Arthur Attema & Mark Oppe & Nancy Devlin & Elly Stolk, 2013, "Time to tweak the TTO: results from a comparison of alternative specifications of the TTO," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 14, issue 1, pages 43-51, July, DOI: 10.1007/s10198-013-0507-y.
  4. Nancy Devlin & Paul Krabbe, 2013, "The development of new research methods for the valuation of EQ-5D-5L," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 14, issue 1, pages 1-3, July, DOI: 10.1007/s10198-013-0502-3.
  5. Federico Augustovski & Lucila Rey-Ares & Vilma Irazola & Mark Oppe & Nancy Devlin, 2013, "Lead versus lag-time trade-off variants: does it make any difference?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 14, issue 1, pages 25-31, July, DOI: 10.1007/s10198-013-0505-0.
  6. Nancy Devlin & Ken Buckingham & Koonal Shah & Aki Tsuchiya & Carl Tilling & Grahame Wilkinson & Ben van Hout, 2013, "A Comparison Of Alternative Variants Of The Lead And Lag Time Tto," Health Economics, John Wiley & Sons, Ltd., volume 22, issue 5, pages 517-532, May, DOI: 10.1002/hec.2819.
  7. Nils Gutacker & Chris Bojke & Silvio Daidone & Nancy J. Devlin & David Parkin & Andrew Street, 2013, "Truly Inefficient Or Providing Better Quality Of Care? Analysing The Relationship Between Risk‐Adjusted Hospital Costs And Patients' Health Outcomes," Health Economics, John Wiley & Sons, Ltd., volume 22, issue 8, pages 931-947, August, DOI: 10.1002/hec.2871.
  8. Nan Luo & Minghui Li & Elly Stolk & Nancy Devlin, 2013, "The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 14, issue 1, pages 15-24, July, DOI: 10.1007/s10198-013-0504-1.
  9. Koonal Shah & Andrew Lloyd & Mark Oppe & Nancy Devlin, 2013, "One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 14, issue 1, pages 65-73, July, DOI: 10.1007/s10198-013-0509-9.
  10. Nils Gutacker & Chris Bojke & Silvio Daidone & Nancy Devlin & Andrew Street, 2013, "Hospital Variation in Patient-Reported Outcomes at the Level of EQ-5D Dimensions," Medical Decision Making, , volume 33, issue 6, pages 804-818, August, DOI: 10.1177/0272989X13482523.
  11. Joan Costa-Font & Mireia Jofre-Bonet, 2013, "Anorexia, Body Image and Peer Effects: Evidence from a Sample of European Women," Economica, London School of Economics and Political Science, volume 80, issue 317, pages 44-64, January, DOI: 10.1111/j.1468-0335.2011.00912.x.
  12. Joan Costa-Font & Mireia Jofre-Bonet & Steven T. Yen, 2013, "Not All Incentives Wash Out the Warm Glow: The Case of Blood Donation Revisited," Kyklos, Wiley Blackwell, volume 66, issue 4, pages 529-551, November.
  13. Christopher Sampson & David Whitehurst & Andrew Street, 2013, "Do patients registered with CAM-trained GPs really use fewer health care resources and live longer? A response to Kooreman and Baars. Eur J Health Econ (2012). 13:469–776," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 14, issue 4, pages 703-705, August, DOI: 10.1007/s10198-013-0466-3.

2012

  1. Patricia Cubí‐Mollá & Carmen Herrero, 2012, "Quality of life lost due to non‐fatal road traffic injuries," Health Economics, John Wiley & Sons, Ltd., volume 21, issue 5, pages 528-550, May, DOI: 10.1002/hec.1729.
  2. Michael Drummond & Adrian Towse, 2012, "Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 13, issue 1, pages 1-5, February, DOI: 10.1007/s10198-011-0353-8.

2011

  1. Nancy J. Devlin & Aki Tsuchiya & Ken Buckingham & Carl Tilling, 2011, "A uniform time trade off method for states better and worse than dead: feasibility study of the ‘lead time’ approach," Health Economics, John Wiley & Sons, Ltd., volume 20, issue 3, pages 348-361, March, DOI: 10.1002/hec.1596.
  2. Adrian Towse & Priya Sharma, 2011, "Incentives for R&D for New Antimicrobial Drugs," International Journal of the Economics of Business, Taylor & Francis Journals, volume 18, issue 2, pages 331-350, DOI: 10.1080/13571516.2011.584434.

2010

  1. Nancy J. Devlin & David Parkin & John Browne, 2010, "Patient‐reported outcome measures in the NHS: new methods for analysing and reporting EQ‐5D data," Health Economics, John Wiley & Sons, Ltd., volume 19, issue 8, pages 886-905, August, DOI: 10.1002/hec.1608.
  2. Phill O’Neill & Nancy Devlin, 2010, "An Analysis of NICE’s ‘Restricted’ (or ‘Optimized’) Decisions," PharmacoEconomics, Springer, volume 28, issue 11, pages 987-993, November, DOI: 10.2165/11536970-000000000-00000.
  3. Carl Tilling & Nancy Devlin & Aki Tsuchiya & Ken Buckingham, 2010, "Protocols for Time Tradeoff Valuations of Health States Worse than Dead: A Literature Review," Medical Decision Making, , volume 30, issue 5, pages 610-619, September, DOI: 10.1177/0272989X09357475.
  4. David Parkin & Nigel Rice & Nancy Devlin, 2010, "Statistical Analysis of EQ-5D Profiles: Does the Use of Value Sets Bias Inference?," Medical Decision Making, , volume 30, issue 5, pages 556-565, September, DOI: 10.1177/0272989X09357473.

2009

  1. Sofia Dimakou & David Parkin & Nancy Devlin & John Appleby, 2009, "Identifying the impact of government targets on waiting times in the NHS," Health Care Management Science, Springer, volume 12, issue 1, pages 1-10, March, DOI: 10.1007/s10729-008-9069-4.
  2. Appleby, John & Devlin, Nancy & Parkin, David & Buxton, Martin & Chalkidou, Kalipso, 2009, "Searching for cost effectiveness thresholds in the NHS," Health Policy, Elsevier, volume 91, issue 3, pages 239-245, August.
  3. Buckingham, Ken J. & Devlin, Nancy Joy, 2009, "A note on the nature of utility in time and health and implications for cost utility analysis," Social Science & Medicine, Elsevier, volume 68, issue 2, pages 362-367, January.

2008

  1. Jofre-Bonet, Mireia & Petry, Nancy M., 2008, "Trading apples for oranges?: Results of an experiment on the effects of Heroin and Cocaine price changes on addicts' polydrug use," Journal of Economic Behavior & Organization, Elsevier, volume 66, issue 2, pages 281-311, May.
  2. Joan Costa‐Font & Mireia Jofre‐Bonet, 2008, "Is There A ‘Secession Of The Wealthy’? Private Health Insurance Uptake And National Health System Support," Bulletin of Economic Research, Wiley Blackwell, volume 60, issue 3, pages 265-287, July, DOI: 10.1111/j.1467-8586.2008.00285.x.

2007

  1. David Parkin & Nancy Devlin, 2007, "‘Is there a case for using visual analogue scale valuations in CUA? Yes there is a case, but what does it add to ordinal data?’ a rejoinder," Health Economics, John Wiley & Sons, Ltd., volume 16, issue 6, pages 649-651, June, DOI: 10.1002/hec.1247.
  2. Adrian Towse, 2007, "If it ain't broke, don't price fix it: the OFT and the PPRS," Health Economics, John Wiley & Sons, Ltd., volume 16, issue 7, pages 653-665, July, DOI: 10.1002/hec.1263.

2006

  1. Beatrice Conradie & Graham Cookson & Colin Thirtle, 2006, "Efficiency And Farm Size In Western Cape Grape Production: Pooling Small Datasets," South African Journal of Economics, Economic Society of South Africa, volume 74, issue 2, pages 334-343, June, DOI: 10.1111/j.1813-6982.2006.00061.x.
  2. Ken Buckingham & Nancy Devlin, 2006, "A theoretical framework for TTO valuations of health," Health Economics, John Wiley & Sons, Ltd., volume 15, issue 10, pages 1149-1154, October, DOI: 10.1002/hec.1122.
  3. David Parkin & Nancy Devlin, 2006, "Is there a case for using visual analogue scale valuations in cost‐utility analysis?," Health Economics, John Wiley & Sons, Ltd., volume 15, issue 7, pages 653-664, July, DOI: 10.1002/hec.1086.
  4. Dakin, Helen Angela & Devlin, Nancy J. & Odeyemi, Isaac A.O., 2006, ""Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making," Health Policy, Elsevier, volume 77, issue 3, pages 352-367, August.
  5. Joan Costa-Font & Mireia Jofre-Bonet, 2006, "Are Private Health Insurance Subscribers Unsatisfied with the Spanish National Health System?," The Geneva Papers on Risk and Insurance - Issues and Practice, Palgrave Macmillan;The Geneva Association, volume 31, issue 4, pages 650-668, October.
  6. Michael Drummond & Anne Mason & Adrian Towse, 2006, "The desirability and feasibility of economic studies of drugs post-launch," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 7, issue 1, pages 5-6, March, DOI: 10.1007/s10198-006-0337-2.

2005

  1. Ashton, Toni & Mays, Nicholas & Devlin, Nancy, 2005, "Continuity through change: The rhetoric and reality of health reform in New Zealand," Social Science & Medicine, Elsevier, volume 61, issue 2, pages 253-262, July.
  2. Nancy Devlin & Paul Hansen & Peter Herbison & Susan Macran, 2005, "A ‘new and improved’ EQ-5D valuation questionnaire?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 6, issue 1, pages 73-82, March, DOI: 10.1007/s10198-004-0263-0.

2004

  1. Nancy J. Devlin, 2004, "Getting Health Economics into Practice, Edited by David Kernick. Radcliffe Medical Press, Oxford, 2002. No. of pages: 358. ISBN 1‐85775‐575‐8," Health Economics, John Wiley & Sons, Ltd., volume 13, issue 5, pages 499-500, May, DOI: 10.1002/hec.902.
  2. Nancy Devlin & David Parkin, 2004, "Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis," Health Economics, John Wiley & Sons, Ltd., volume 13, issue 5, pages 437-452, May, DOI: 10.1002/hec.864.
  3. Parkin, David & Rice, Nigel & Jacoby, Ann & Doughty, Julie, 2004, "Use of a visual analogue scale in a daily patient diary: modelling cross-sectional time-series data on health-related quality of life," Social Science & Medicine, Elsevier, volume 59, issue 2, pages 351-360, July.
  4. Diego Ossa & Adrian Towse, 2004, "Genetic screening, health care and the insurance industry," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 5, issue 2, pages 116-121, May, DOI: 10.1007/s10198-003-0213-2.

2003

  1. Nancy J. Devlin & Paul Hansen & Paul Kind & Alan Williams, 2003, "Logical inconsistencies in survey respondents' health state valuations ‐ a methodological challenge for estimating social tariffs," Health Economics, John Wiley & Sons, Ltd., volume 12, issue 7, pages 529-544, July, DOI: 10.1002/hec.741.
  2. Mireia Jofre-Bonet & Martin Pesendorfer, 2003, "Estimation of a Dynamic Auction Game," Econometrica, Econometric Society, volume 71, issue 5, pages 1443-1489, September.
  3. Wolfgang Greiner & Tom Weijnen & Martin Nieuwenhuizen & Siem Oppe & Xavier Badia & Jan Busschbach & Martin Buxton & Paul Dolan & Paul Kind & Paul Krabbe & Arto Ohinmaa & David Parkin & Montserat Roset, 2003, "A single European currency for EQ-5D health states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 4, issue 3, pages 222-231, September, DOI: 10.1007/s10198-003-0182-5.

2002

  1. Nancy J. Devlin, 2002, "The Purchasing of Health Care by Primary Care Organisations. An evaluation and Guide to Future Policy, by N. Mays, S. Wyke, G. Malbon, N. Goodwin. Open University Press, Buckingham and Philadelphia, 2001. No. of pages: 320. ISBN 0‐335‐20900‐9," Health Economics, John Wiley & Sons, Ltd., volume 11, issue 6, pages 567-568, September, DOI: 10.1002/hec.722.
  2. Angela Robinson & David Parkin, 2002, "Recognising diversity in public preferences: the use of preference sub‐groups in cost‐effectiveness analysis. A response to Sculpher and Gafni," Health Economics, John Wiley & Sons, Ltd., volume 11, issue 7, pages 649-651, October, DOI: 10.1002/hec.735.

2001

  1. Nancy Devlin & Paul Hansen, 2001, "Health care spending and economic output: Granger causality," Applied Economics Letters, Taylor & Francis Journals, volume 8, issue 8, pages 561-564, DOI: 10.1080/13504850010017357.

2000

  1. Jofre-Bonet, Mireia & Pesendorfer, Martin, 2000, "Bidding behavior in a repeated procurement auction: A summary," European Economic Review, Elsevier, volume 44, issue 4-6, pages 1006-1020, May.
  2. Jofre-Bonet, Mireia, 2000, "Health care: private and/or public provision," European Journal of Political Economy, Elsevier, volume 16, issue 3, pages 469-489, September.
  3. Mireia Jofre-Bonet, 2000, "Public health care and private insurance demand: The waiting time as a link," Health Care Management Science, Springer, volume 3, issue 1, pages 51-71, January, DOI: 10.1023/A:1019024903898.

1999

  1. Scuffham, P. & Devlin, N. & Eberhart-Phillips, J. & Wilson-Salt, R., 1999, "The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule," Social Science & Medicine, Elsevier, volume 49, issue 6, pages 763-779, September.
  2. David Parkin & Nigel Rice & Matthew Sutton, 1999, "Non‐ and semi‐parametric estimation of age and time heterogeneity in repeated cross‐sections: an application to self‐reported morbidity and general practitioner utilization1," Health Economics, John Wiley & Sons, Ltd., volume 8, issue 5, pages 429-440, August, DOI: 10.1002/(SICI)1099-1050(199908)8:5<.
  3. Mason, Anne & Drummond, Michael & Towse, Adrian, 1999, "Is disease management relevant in Europe: some evidence from the United Kingdom," Health Policy, Elsevier, volume 48, issue 1, pages 69-77, July.
  4. Adrian Towse & Patricia Danzon, 1999, "Medical negligence and the NHS: an economic analysis," Health Economics, John Wiley & Sons, Ltd., volume 8, issue 2, pages 93-101, March, DOI: 10.1002/(SICI)1099-1050(199903)8:2<.

1997

  1. Miller, Paul & Parkin, David & Craig, Neil & Lewis, David & Gerard, Karen, 1997, "Less fog on the Tyne? Programme budgeting in Newcastle and North Tyneside," Health Policy, Elsevier, volume 40, issue 3, pages 217-229, June.
  2. David Parkin & Bruce Hollingsworth, 1997, "Measuring production efficiency of acute hospitals in Scotland, 1991-94: validity issues in data envelopment analysis," Applied Economics, Taylor & Francis Journals, volume 29, issue 11, pages 1425-1433, DOI: 10.1080/000368497326255.

1996

  1. Szeto, Kam Leong & Devlin, Nancy J., 1996, "The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand," Health Policy, Elsevier, volume 38, issue 2, pages 101-115, November.

1995

  1. Nancy Devlin & Paul Hansen & Stephen Knowles, 1995, "Comment: Financing New Zealand’s Tertiary Education: How Much Subsidy?," Agenda - A Journal of Policy Analysis and Reform, Australian National University, College of Business and Economics, School of Economics, volume 2, issue 2, pages 223-225.
  2. Craig, Neil & Parkin, David & Gerard, Karen, 1995, "Clearing the fog on the Tyne: programme budgeting in Newcastle and North Tyneside Health Authority," Health Policy, Elsevier, volume 33, issue 2, pages 107-125, August.
  3. Anthony Scott & David Parkin, 1995, "Investigating hospital efficiency in the new NHS: The role of the translog cost function," Health Economics, John Wiley & Sons, Ltd., volume 4, issue 6, pages 467-478, November, DOI: 10.1002/hec.4730040604.

1994

  1. Devlin, N.J., 1994, "The effects of denturism: New Zealand dentists' response to competition," American Journal of Public Health, American Public Health Association, volume 84, issue 10, pages 1675-1677.
  2. Adrian Towse, 1994, "The Political Economy of Healthcare. By David Resisman. MacMillan Press, London, 1993. No. of pages: 267. ISBN: 0‐333‐58579‐8," Health Economics, John Wiley & Sons, Ltd., volume 3, issue 5, pages 347-348, September, DOI: 10.1002/hec.4730030509.

1991

  1. Bryan, Stirling & Parkin, David & Donaldson, Cam, 1991, "Chiropody and the QALY: a case study in assigning categories of disability and distress to patients," Health Policy, Elsevier, volume 18, issue 2, pages 169-185, July.

1989

  1. Parkin, David, 1989, "Comparing Health Service Efficiency Across Countries," Oxford Review of Economic Policy, Oxford University Press and Oxford Review of Economic Policy Limited, volume 5, issue 1, pages 75-88, Spring.

1987

  1. Parkin, David & McGuire, Alistair & Yule, Brian, 1987, "Aggregate health care expenditures and national income : Is health care a luxury good?," Journal of Health Economics, Elsevier, volume 6, issue 2, pages 109-127, June.

1985

  1. Yule, Brian & Parkin, David, 1985, "The demand for dental care: An assessment," Social Science & Medicine, Elsevier, volume 21, issue 7, pages 753-760, January.

Books

2014

  1. Wren, Maev-Ann & Gillespie, Paddy & Smith, Samantha & Kearns, Karen & Crichton,Siobhan & Parkin, David & Hickey, Anne & Horgan, Frances & Wiley, Miriam, 2014, "Towards Earlier Discharge, Better Outcomes, Lower Cost: Stroke Rehabilitation in Ireland," Research Series, Economic and Social Research Institute (ESRI), number BKMNEXT277.

2012

  1. Jorge Mestre-Ferrandiz;Jon Sussex;Adrian Towse, 2012, "The R&D Cost of a New Medicine," Monograph, Office of Health Economics, number 000135, Dec.

2011

  1. Nancy Devlin;Jon Sussex, 2011, "Incorporating Multiple Criteria in HTA: Methods and Processes," Monograph, Office of Health Economics, number 000189, Mar.
  2. Priya Sharma;Adrian Towse, 2011, "New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options," Monograph, Office of Health Economics, number 000184, Apr.

2010

  1. Nancy Devlin;John Appleby, 2010, "Getting the Most out of PROMs: Putting Health Outcomes at the Heart of NHS Decision-Making," Monograph, Office of Health Economics, number 000220, Mar.
  2. Phill O’Neill, 2010, "Shedding the Pounds: Obesity Management, NICE Guidance and Bariatric Surgery in England," Monograph, Office of Health Economics, number 000204, Nov.
  3. Adrian Towse;Nancy Mattison;Jorge Mestre-Ferrandiz, 2010, "Biosimilars: How Much Entry and Price Competition Will Result?," Monograph, Office of Health Economics, number 000195, Dec.

2006

  1. Anne R. Mason;Michael F. Drummond;Adrian Towse, 2006, "Economic Post-Launch Studies: Matching the Desirable with the Feasible," Monograph, Office of Health Economics, number 000268, Sep.

2004

  1. John Appleby;Nancy Devlin;Diane Dawson, 2004, "How Much Should We Spend on the NHS?," Monograph, Office of Health Economics, number 000490, Jul.

2002

  1. Clive Pritchard;Nancy Devlin;Adrian Towse, 2002, "Cost-Effectiveness Thresholds: Economic and ethical issues," Monograph, Office of Health Economics, number 000473, Nov.
  2. Anne R. Mason;Michael F. Drummond;Jonathan Cooke;Adrian Towse, 2002, "Influencing Prescribing in a Primary Care Led NHS," Monograph, Office of Health Economics, number 000476, Nov.
  3. Hannah Kettler;Adrian Towse, 2002, "Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty," Monograph, Office of Health Economics, number 000479, Dec.

1999

  1. Anne R. Mason;Michael F. Drummond;Adrian Towse, 1999, "Disease Management, the NHS and the Pharmaceutical Industry," Monograph, Office of Health Economics, number 000446, Mar.

1997

  1. Adrian Towse, 1997, "Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?," Monograph, Office of Health Economics, number 000423, May.

1995

  1. Adrian Towse, 1995, "Financing Health Care in the UK: A Discussion of NERA’s Prototype Model to Replace the NHS," Monograph, Office of Health Economics, number 000409, Jan.
  2. Adrian Towse, 1995, "Industrial Policy and the Pharmaceutical Industry," Monograph, Office of Health Economics, number 000414, Jan.
  3. David Hale;Adrian Towse, 1995, "Value of the Pharmaceutical Industry to the UK Economy," Monograph, Office of Health Economics, number 000415, Jun.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.